There is no single PSA test normal range that fits every man. PSA levels rise gently with age and prostate size, so doctors read your number alongside your age, symptoms and risk. A raised PSA is a signal to look further, not a diagnosis of cancer.
Quick answer
There is no single PSA test normal range. PSA naturally rises with age and prostate size. As a rough guide, UK NICE guidance uses age-based thresholds of about 2.5 ng/mL (40s), 3.5 (50s), 4.5 (60s) and 6.5 (70s). A raised result needs a repeat test and a doctor's review, not panic.
November is widely observed as a men’s health awareness month, often called Movember. It is a good time to understand what a PSA result really tells you. This guide explains the numbers, the common reasons for high PSA levels, and what usually happens next.
PSA stands for prostate-specific antigen. It is a protein made by cells of the prostate gland. A small amount normally leaks into the blood.
A PSA test is a simple blood test that measures this protein in nanograms per millilitre (ng/mL). You can usually eat and drink normally before it.
PSA is not a cancer test as such. Cancer can raise it, but so can several harmless or treatable conditions. Some men with prostate cancer also have a “normal” PSA.
For many years, 4.0 ng/mL was used as a general cut-off. The US National Cancer Institute (NCI) still notes that a PSA above 4.0 is generally considered abnormal. It also notes that doctors may use lower cut-offs for younger men and higher ones for older men.
There are three main reasons one number does not work for everyone:
A British Association of Urological Surgeons (BAUS) patient leaflet states that about two in three men with a raised PSA do not have prostate cancer.
The table below shows age-specific thresholds used in UK NICE guidance (NG12) for men with possible prostate symptoms. These are approximate guides based on indirect trial evidence, not strict limits.
| Age group | PSA level usually considered raised (approximate) |
|---|---|
| Under 40 | No fixed value – clinical judgement |
| 40–49 | Above 2.5 ng/mL |
| 50–59 | Above 3.5 ng/mL |
| 60–69 | Above 4.5 ng/mL |
| 70–79 | Above 6.5 ng/mL |
| Over 79 | No fixed value – clinical judgement |
For men without symptoms, the UK’s Prostate Cancer Risk Management Programme uses a single threshold of 3 ng/mL. Laboratories in India may print their own reference range on the report. Always discuss your number with your doctor rather than relying on a chart alone.
Many everyday and benign conditions can push PSA up for a while. Prostate Cancer UK, the NCI and BAUS list the following:
Guidance from Prostate Cancer UK and BAUS suggests you avoid the following before testing:
Tell the person drawing your blood about any recent infection, procedure or prostate medicine.
When the total PSA is in a “grey zone”, doctors may use extra measures to judge risk more precisely.
PSA circulates in two forms: bound to proteins, or “free”. The free-to-total ratio is mainly used when total PSA is between about 4 and 10 ng/mL. According to Mayo Clinic Laboratories, the lower the free PSA percentage, the higher the chance of cancer. A normal ratio still does not rule cancer out completely.
PSA density is your PSA divided by the prostate volume, measured on ultrasound or MRI. A large prostate from BPH can explain a moderately high PSA. Cut-offs of about 0.15 or 0.20 are commonly used. A higher density raises concern and may support a biopsy.
A single high reading rarely leads straight to a biopsy. The usual path looks like this:
The European Association of Urology (EAU) also lists risk calculators and extra blood or urine biomarkers as options. These help decide who truly needs a biopsy.
If a cancer is found, many low-risk cancers can be monitored rather than treated straight away. Where treatment is needed, your team will discuss options such as robotic and laparoscopic cancer surgery, radiotherapy or surveillance. Each has benefits and risks.
PSA-based prostate cancer screening is a personal choice. Major guidelines from the AUA and EAU stress shared decision-making – talking through benefits and harms with your doctor first.
Higher-risk groups include men with a father or brother affected, men of Black African ancestry, and those with inherited gene changes such as BRCA2.
Your urologist will advise based on your age, health and test results.
See a doctor if you have a raised PSA result, or symptoms such as:
These symptoms are more often caused by BPH or infection. They still deserve a proper check.
There is no exact normal value. UK NICE guidance treats a PSA above about 4.5 ng/mL as raised for men aged 60–69 with symptoms. For symptom-free men, a lower threshold of 3 ng/mL is often used. Your doctor will interpret it with your other risk factors.
Yes. A urinary or prostate infection can raise PSA for several weeks. BAUS advises waiting about six weeks after an infection before testing. Your doctor will usually repeat the PSA test once the infection has cleared.
No. About two in three men with a raised PSA do not have prostate cancer, according to BAUS. BPH, prostatitis, infection, recent ejaculation or cycling can all raise it. Further tests such as a repeat PSA and MRI help clarify the cause.
Yes, for a short time. Prostate Cancer UK advises avoiding ejaculation and vigorous exercise, including cycling, for 48 hours before the test. This helps avoid a falsely high reading.
Guidelines differ slightly. The AUA suggests a baseline test at 45–50, and earlier at 40–45 for higher-risk men. The EAU suggests about 50 for most men. Discuss the benefits and harms with your doctor before deciding.
About the specialist: Dr Sreeharsha Harinatha – MBBS, MS (General Surgery), MCh (Urology), Diploma in Robotic Surgery (France) – is a Senior Consultant in Urology, Uro-Oncology, Robotic Surgery and Renal Transplantation at Apollo Hospitals, Bannerghatta Road and Jayanagar, Bengaluru, with 17+ years of experience. Karnataka Medical Council Reg. No. KMC72009.
Related care: Robotic & Laparoscopic Uro-Oncology · About Dr Sreeharsha Harinatha · Contact the clinic
Published 03 November 2026. This article is general information and does not replace a personal consultation.